ABSI - Absci Price-to-Projected Revenue Ratio

Absci utilizes an AI platform for accelerated drug synthesis, leveraging support from leading pharma behemoths. The expected P/S valuation reflects market expectations, where 1000.40 determines this parameter level. Absci is reducing R&D expenditures in immuno-oncology, monetizing its breakthrough developments through B2B partnerships in the digital antibody design segment.

absci.com - ABSI Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Absci Bio (ABSI)

- current price and projected stock value:

Stock Price Absci Corporation|ABSI - Price Target Chart

- market capitalization statistics:

Market Value Absci Bio|ABSI - Company Buyout Price

- book value of equity indicators:

Book Value per Share Absci|ABSI - Book Valuation of Business|Market Capitalization to Book Value Ratio absci.com|ABSI - Company Total Asset Base

- company liabilities and liquidity data:

- financial results and valuation multiples details:

ABSI - Company Profit|Projected Future Earnings Absci|ABSI - P/E Multiple|Forward P/E Multiple Absci Corp.|ABSI - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Absci Bio|ABSI - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Absci|ABSI - Net earnings per share for the last 12 months|Quarterly EPS earnings growth absci.com|ABSI - Expected net earnings per share growth this year|Earnings growth forecast for next year Absci

- sales volume and revenue indicators:

ABSI - Revenue and Sales Volume|Projected Sales Volume Absci Corporation|ABSI - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Absci Bio

Summary company analysis:ABSI (Absci Corporation)

Valuing Absci (ABSI) assets requires accounting for the synergy between AI-driven antibody design and ESG optimization, which reduces reagent costs. By analyzing the expected P/S ratio, an investor can observe the dynamic business value relative to projected revenue, enabling a real-time assessment of the cloud platform's scaling potential against the risks of overcapitalization or frozen invested capital.

Competitors of Absci (ABSI)

Forward P/S Multiple VEEV (Veeva)|Doximity Inc - Price-to-Projected Revenue Ratio|HQY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Waystar Corp WAY|CRVL: Forward P/S Multiple|PRVA - Market Cap to Expected Sales Ratio|HURN (Huron) - Forward P/S Multiple|Certara Inc (CERT) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple OMCL (Omnicell Corp)|Price to Expected Revenue Ratio GDRX|Schrodinger, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales PHR|OMDA - Price-to-Projected Revenue Ratio|Evolent Health Inc (EVH) - Forward Price-to-Revenue Multiple|HSTM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Definitive Corp (DH)|CCSI (Consensus Cloud Solutions) - Forward P/S Multiple|Market Cap to Projected Revenue AGL (agilonhealth.com)|Forward P/S Multiple SY|Forward P/S Multiple NRC Health (NRC)|Forward P/S Multiple SPOK (Spok Corp)|OptimizeRx Inc. - Price-to-Projected Revenue Ratio|TBRG - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio simulations-plus.com SLP|SOPH: Forward P/S Multiple|Forward Price-to-Revenue Multiple Health Catalyst Inc.|CCLD (CareCloud Inc.) - Forward P/S Multiple|Research Solutions Inc. (RSSS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple DLHC|Forward P/S Multiple onemednet.com (ONMD)|Forward P/S Multiple SCNX (Scienture)|Healthcare Triangle Inc - Price-to-Projected Revenue Ratio|ISPC - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Bullfrog AI Holdings BFRG|WORX: Forward P/S Multiple|MSPR - Market Cap to Expected Sales Ratio|ICCT (iCoreConnect, Inc.) - Forward P/S Multiple|TRxADE HEALTH Inc (MEDS) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ORGS (Orgenesis Corp)|Price to Expected Revenue Ratio RCM|Sharecare, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales STRM|SYRA - Price-to-Projected Revenue Ratio|Apollo Medical Holdings (AMEH) - Forward Price-to-Revenue Multiple|MODN: Forward P/S Multiple|Market Cap to Future Revenue Ratio NextGen Healthcare Corp (NXGN)